In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...
Read MoreIn a nutshell This trial is investigating the effects of AVD [doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC)] with brentuximab vedotin (Adcetris) induction chemotherapy, plus nivolumab (Opdivo) for Hodgkin lymphoma (HL). The main outcome to be measured is survival without cancer worsening 3 years after treatment. The details...
Read More
In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...
Read MoreIn a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma...
Read MoreIn a nutshell This Phase 3 trial is evaluating the effectiveness of brentuximab vedotin (Adcetris) with or without nivolumab (Opdivo) for patients with relapsed or unresponsive classical Hodgkin’s lymphoma (cHL). The main outcome to be measured will be survival outcomes at 4 years after treatment. The details Treatment remains...
Read More
In a nutshell This study investigated the impact of interim functional imaging (IFI) on the outcomes of treatment for advanced classical Hodgkin lymphoma (cHL). This study found that patients with positive scan results were more likely to disease progression. Some background ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the...
Read More
In a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read More
In a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreIn a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of Hodgkin lymphoma (HL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they specifically...
Read MoreIn a nutshell This study investigated if patients with Hodgkin lymphoma (HL) found in the bones have worse outcomes than patients with HL in the lymph nodes. It was found that having bone HL did not reduce survival of patients. Some background Many patients with HL are cured by treatment. After 5 years, almost 86% of patients survive. When...
Read More
